Subchronic memantine administration on spatial learning, exploratory activity, and nest-building in an APP/PS1 mouse model of Alzheimer's disease

Neuropharmacology

Volumn 60, Issue 6, 2011, Pages 930-936

  Filali, Mohammed ^a   Lalonde, Robert ^b   Rivest, Serge ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Alzheimer's disease; Anxiety; Exploratory activity; Learning and memory; Memantine; Nesting behavior; T water maze; Transgenic mice

Indexed keywords

AMYLOID PRECURSOR PROTEIN; MEMANTINE; PLACEBO;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; EXPLORATORY BEHAVIOR; LEARNING; LONG TERM CARE; MALE; MAZE TEST; MOUSE; NESTING; NONHUMAN; PRIORITY JOURNAL; TASK PERFORMANCE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AVOIDANCE LEARNING; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MAZE LEARNING; MEMANTINE; MICE; MICE, NEUROLOGIC MUTANTS; NESTING BEHAVIOR; PRESENILIN-1;

EID: 79952449645     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2011.01.035     Document Type: Article

References (69)

1. G.M. Alley, J.A. Bailey, D. Chen, B. Ray, L.K. Puli, H. Tanila, P.K. Banerjee, and D.K. Lahiri Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice J. Neurosci. Res. 88 2010 143 154
2. F. Antonanzas, B. Rive, J.M. Badenas, S. Gomez-Lus, and C. Guilhaume Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain Eur. J. Health Econ. 7 2006 137 144 (Pubitemid 44562258)
3. M. Arif, T. Chikuma, M.M. Ahmed, M. Nakazato, M.A. Smith, and T. Kato Effects of memantine on soluble Aβ(25-35)-induced changes in peptidergic and glial cells in Alzheimer's disease model rat brain regions Neuroscience 164 2009 1199 1209
4. S. Bakchine, and H. Loft Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study J. Alzheimers Dis. 13 2008 97 107 (Pubitemid 351365621)
5. C. Ballard, and A. Corbett Management of neuropsychiatric symptoms in people with dementia CNS Drugs 24 2010 729 739
6. D.R. Borchelt, G. Thinakaran, C.B. Eckman, M.K. Lee, F. Davenport, T. Ratovitsky, C.M. Prada, G. Kim, S. Seekins, D. Yager, H.H. Slunt, R. Wang, M. Seeger, A.I. Levey, S.E. Gandy, N.G. Copeland, N.A. Jenkins, D.L. Price, S.G. Younkin, and S.S. Sisodia Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins Neuron 19 1997 939 945 (Pubitemid 27471397)
7. M. Cente, S. Mandakova, and P. Filipcik Memantine prevents sensitivity to excitotoxic cell death of rat cortical neurons expressing human truncated tau protein Cell. Mol. Neurobiol. 29 2009 945 949
8. H.S. Chen, Y.F. Wang, P.V. Rayudu, P. Edgecomb, J.C. Neill, M.M. Segal, S.A. Lipton, and F.E. Jensen Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation Neuroscience 86 1998 1121 1132 (Pubitemid 28318538)
9. K.M. Cosman, L.L. Boyle, and A.P. Porsteinsson Memantine in the treatment of mild-to-moderate Alzheimer's disease Expert Opin. Pharmacother. 8 2007 203 214 (Pubitemid 46206622)
10. A.C. Costa, J.J. Scott-McKean, and M.R. Stasko Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test Neuropsychopharmacology 33 2008 1624 1632 (Pubitemid 351684704)
11. Cotel, M.C., Jawhar, S., Christensen, D.Z., Bayer, T.A., Wirths, O. Environmental enrichment fails to rescue working memory deficits, neuron loss, and neurogenesis in APP/PS1KI mice. Neurobiol. Aging, in press.
12. C. Creeley, D.F. Wozniak, J. Labruyere, G.T. Taylor, and J.W. Olney Low doses of memantine disrupt memory in adult rats J. Neurosci. 26 2006 3923 3932 (Pubitemid 44315412)
13. J.L. Cummings, J. Mackell, and D. Kaufer Behavioral effects of current Alzheimer's disease treatments: a descriptive review Alzheimers Dement 4 2008 49 60
14. R.M.J. Deacon, L.L. Cholerton, K. Talbot, R.G. Nair-Roberts, D.J. Sanderson, C. Romberg, E. Koros, K.D. Bornemann, and J.N.P. Rawlins Age-dependent and -independent behavioral deficits in Tg2576 mice Behav. Brain Res. 189 2008 126 138
15. M. Degerman Gunnarsson, L. Kilander, H. Basun, and L. Lannfelt Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease Dement Geriatr. Cogn. Disord. 24 2007 247 252 (Pubitemid 47482070)
16. H. Dong, C.M. Yuede, C. Coughlan, B. Lewis, and J.G. Csernansky Effects of memantine on neuronal structure and conditioned fear in the Tg2576 mouse model of Alzheimer's disease Neuropsychopharmacology 33 2008 3226 3236
17. B.D. Drever, W.G. Anderson, H. Johnson, M. O'Callaghan, S. Seo, D.Y. Choi, G. Riedel, and B. Platt Memantine acts as a cholinergic stimulant in the mouse hippocampus J. Alzheimers Dis. 12 2007 319 333
18. M. Dumont, C. Strazielle, M. Staufenbiel, and R. Lalonde Spatial learning and exploration of environmental stimuli in 24-month-old female APP23 transgenic mice with the Swedish mutation Brain Res. 1024 2004 113 121 (Pubitemid 39286720)
19. M. Emre, P. Mecocci, and K. Stender Pooled analyses on cognitive effects of memantine in patients with moderate to severe Alzheimer's disease J. Alzheimers Dis. 14 2008 193 199 (Pubitemid 352040033)
20. M. Emre, M. Tsolaki, U. Bonuccelli, A. Destée, E. Tolosa, A. Kutzelnigg, A. Ceballos-Baumann, S. Zdravkovic, A. Bladström, R. Jones, and 11018 Study Investigators Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial Lancet Neurol. 9 2010 969 977
21. H.H. Feldman, F.A. Schmitt, and J.T. Olin Memantine MEM-MD-02 Study Group. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment Alzheimer Dis. Assoc. Disord. 20 2006 263 268 (Pubitemid 44900940)
22. S. Ferris, R. Ihl, P. Robert, B. Winblad, G. Gatz, F. Tennigkeit, and S. Gauthier Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients Alzheimers Dement 5 2009 369 374
23. M. Filali, R. Lalonde, and S. Rivest Cognitive and non-cognitive behaviors in an APPswe/PS1 bigenic model of Alzheimer's disease Genes Brain Behav. 8 2009 143 148
24. M. Gagnon, B. Rive, M. Hux, and C. Guilhaume Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada Can. J. Psychiatry 52 2007 519 526 (Pubitemid 47403186)
25. F.J. Gil-Bea, B. Aisa, R. Schliebs, and M.J. Ramirez Increase of locomotor activity underlying the behavioral dishinbition in Tg2576 mice Behav. Neurosci. 121 2007 340 344 (Pubitemid 47445085)
26. B. Kolb Functions of the frontal cortex of the rat: a comparative review Brain Res. 320 1984 65 98 (Pubitemid 15188148)
27. Z. Kubova, J. Kremlacek, M. Valis, J. Szanyi, J. Langrova, F. Vit, and M. Kuba Effect of memantine in Alzheimer's disease evaluated by visual-evoked potentials to pattern-reversal, motion-onset, and cognitive stimuli J. Clin. Neurophysiol. 27 2010 334 340
28. R. Lalonde, T. Lewis, C. Strazielle, H. Kim, and K. Fukuchi Transgenic mice expressing the βAPP695SWE mutation: effects on exploratory activity, anxiety, and motor coordination Brain Res. 977 2003 38 45 (Pubitemid 36638692)
29. J.M. Lassalle, H. Halley, S. Daumas, L. Verret, and B. Francés Effects of the genetic background on cognitive performances of TG2576 mice Behav. Brain Res. 191 2008 104 110
30. F. Léveillé, F. El Gaamouch, E. Gouix, M. Lecocq, D. Lobner, O. Nicole, and A. Buisson Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors FASEB J. 22 2008 4258 4271
31. H.P. Liu, W.Y. Lin, S.H. Liu, W.F. Wang, C.H. Tsai, B.T. Wu, C.K. Wang, and F.J. Tsai Genetic variation in N-methyl-D-aspartate receptor subunit NR3A but not NR3B influences susceptibility to Alzheimer's disease Dement. Geriatr. Cogn. Disord. 28 2009 521 527
32. L. Liu, S. Ikonen, T. Heikkinen, T. Tapiola, T. van Groen, and H. Tanila The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice Exp. Neurol. 173 2002 196 204 (Pubitemid 34151371)
33. I.D. Maidment, C.G. Fox, M. Boustani, J. Rodriguez, R.C. Brown, and C.L. Katona Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis Ann. Pharmacother. 42 2008 32 38
34. H. Martinez-Coria, K.N. Green, L.M. Billings, M. Kitazawa, M. Albrecht, G. Rammes, C.G. Parsons, S. Gupta, P. Banerjee, and F.M. LaFerla Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice Am. J. Pathol. 176 2010 870 880
35. A. Marutle, C. Unger, E. Hellstrom-Lindahl, J. Wang, J. Puolivali, H. Tanila, A. Nordberg, and X. Zhang Elevated levels of Ab1-40 and Ab1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice Neurosci. Lett. 328 2002 269 272 (Pubitemid 34876663)
36. K. McKeage Memantine: a review of its use in moderate to severe Alzheimer's disease CNS Drugs 23 2009 881 897
37. R. McShane, A. Areosa Sastre, and N. Minakaran Memantine for dementia Cochrane Database Syst. Rev. 19 2006 CD003154
38. P. Mecocci, A. Bladström, and K. Stender Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies Int. J. Geriatr. Psychiatry 24 2009 532 538
39. R. Minkeviciene, P. Banerjee, and H. Tanila Memantine improves spatial learning in a transgenic mouse model of Alzheimer's disease J. Pharmacol. Exp. Ther. 311 2004 677 682 (Pubitemid 39391555)
40. P.J. Modrego, N. Fayed, J.M. Errea, C. Rios, M.A. Pina, and M. Sarasa Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy Eur. J. Neurol. 17 2010 405 412
41. R. Monastero, C. Camarda, C. Pipia, and R. Camarda Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases J. Neurol. Neurosurg. Psychiatry 78 2007 546 (Pubitemid 46662914)
42. R.G. Morris, E. Anderson, G.S. Lynch, and M. Baudry Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5 Nature 319 1986 774 776 (Pubitemid 16145031)
43. E. Ognibene, S. Middei, S. Daniele, W. Adriani, O. Ghirardi, A. Caprioli, and G. Laviola Aspects of spatial memory and behavioral disinhibition in Tg2576 transgenic mice as a model of Alzheimer's disease Behav. Brain Res. 156 2005 225 232 (Pubitemid 39576062)
44. B.R. Ott, L.M. Blake, E. Kagan, M. Resnick, and Memantine MEM-MD-11AB Study Group Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease J. Neurol. 254 2007 351 358 (Pubitemid 46399200)
45. S. Ozturk, and A.E. Cillier Magnesium supplementation in the treatment of dementia patients Med. Hypoth. 67 2006 1223 1225 (Pubitemid 44302245)
46. S.G. Papageorgiou, T. Kontaxis, A. Antelli, and N. Kalfakis Exacerbation of myoclonus by memantine in a patient with Alzheimer disease J. Clin. Psychopharmacol. 27 2007 407 408 (Pubitemid 47075519)
47. C.G. Parsons, A. Stöffler, and W. Danysz Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse Neuropharmacology 53 2007 699 723 (Pubitemid 47532143)
48. E.R. Peskind, S.G. Potkin, N. Pomara, B.R. Ott, S.M. Graham, J.T. Olin, and S. McDonald Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial Am. J. Geriatr. Psychiatry 14 2006 704 715 (Pubitemid 44196270)
49. N. Pomara, B.R. Ott, E. Peskind, and E.M. Resnick Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial Alzheimer Dis. Assoc. Disord. 21 2007 60 64 (Pubitemid 46398957)
50. J. Puoliväli, J. Wang, T. Heikkinen, M. Heikkilä, T. Tapiola, T. van Groen, and H. Tanila Hippocampal Aβ42 levels correlate with spatial memory deficit in APP and PS1 double transgenic mice Neurobiol. Dis. 9 2002 339 347 (Pubitemid 34442081)
51. B. Ray, P.K. Banerjee, N.H. Greig, and D.K. Lahiri Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells Neurosci. Lett. 470 2010 1 5
52. D.M. Robinson, and G.M. Keating Memantine: a review of its use in Alzheimer's disease Drugs 66 2006 1515 1534 (Pubitemid 44250755)
53. D.C. Rogers, E.M.C. Fisher, S.D.M. Brown, J. Peters, A.J. Hunter, and J.E. Martin Behavioral and functional analysis of mouse phenotype: SHIRPA, a proposed protocol for comprehensive phenotype assessment Mamm. Genome 8 1997 711 713 (Pubitemid 127739700)
54. F. Schmitt, M. Ryan, and G. Cooper A brief review of the pharmacologic and therapeutic aspects of memantine in Alzheimer's disease Expert Opin. Drug Metab. Toxicol. 3 2007 135 141 (Pubitemid 47307460)
55. H. Scholtzova, Y.Z. Wadghiri, M. Douadi, E.M. Sigurdsson, Y.S. Li, D. Quartermain, P. Banerjee, and T. Wisniewski Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging J. Neurosci. Res. 86 2008 2784 2791
56. M.S. Song, G. Rauw, G.B. Baker, and S. Kar Memantine protects rat cortical cultured neurons against beta-amyloid-induced toxicity by attenuating tau phosphorylation Eur. J. Neurosci. 28 2008 1989 2002
57. R.J. Steele, and R.G. Morris Delay-dependent impairment of a matching-to-place task with chronic and intrahippocampal infusion of the NMDA-antagonist D-AP5 Hippocampus 9 1999 118 136 (Pubitemid 29196956)
58. M.M. Swanberg Memantine for behavioral disturbances in frontotemporal dementia: a case series Alzheimer Dis. Assoc. Disord. 21 2007 164 166 (Pubitemid 46878979)
59. V. Szegedi, G. Juhasz, C.G. Parsons, and D. Budai In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons J. Neural. Transm. 117 2010 1189 1194
60. S.J. Thomas, and G.T. Grossberg Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias Clin. Interv. Aging 4 2009 367 377
61. C. Unger, M.M. Svedberg, W.F. Yu, M.M. Hedberg, and A. Nordberg Effect of subchronic treatment of memantine, galantamine, and nicotine in the brain of Tg2576 (APPswe) transgenic mice J. Pharmacol. Exp. Ther. 317 2006 30 36
62. C.H. van Dyck, P.N. Tariot, B. Meyers, E. Malca Resnick, and Memantine MEM-MD-01 Study Group A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease Alzheimer Dis. Assoc. Disord. 21 2007 136 143 (Pubitemid 46878975)
63. D. Van Dam, and P.P. De Deyn Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model Eur. Neuropsychopharmacol. 16 2006 59 69 (Pubitemid 43005096)
64. J. Wang, H. Tanila, J. Puoliväli, I. Kadish, and T. van Groen Gender differences in the amount and deposition of amyloidb in APPswe and PS1 double transgenic mice Neurobiol. Dis. 14 2003 318 327 (Pubitemid 37543511)
65. D. Weycker, C. Taneja, J. Edelsberg, M.H. Erder, F.A. Schmitt, J. Setyawan, and G. Oster Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil Curr. Med. Res. Opin. 23 2007 1187 1197 (Pubitemid 46799603)
66. B. Winblad, R.W. Jones, Y. Wirth, A. Stöffler, and H.J. Möbius Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials Dement. Geriatr. Cogn. Disord. 24 2007 20 27 (Pubitemid 46985287)
67. T.Y. Wu, and C.P. Chen Dual action of memantine in Alzheimer disease: a hypothesis Taiwan J. Obstet. Gynecol. 48 2009 273 277
68. P. Xia, H.S. Chen, D. Zhang, and S.A. Lipton Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses J. Neurosci. 30 2010 11246 11250
69. P.R. Zoladz, A.M. Campbell, C.R. Park, D. Schaefer, W. Danysz, and D.M. Diamond Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane Pharmacol. Biochem. Behav. 85 2006 298 306 (Pubitemid 44881071)